Discussion about this post

User's avatar
Neural Foundry's avatar

The Novartis deal at $72/share for Avidity being lumped with Berkshire's cash deployment tells the real story about 2025 biotech flows. The valuation multiple here implies markets are pricing platform technology as strategic infrastructure rather than single asset plays. What's interesting is how this M&A alpha lifts the entire biotech sector when you have multiple bids competing simultanously across rare disease spaces, essentially validating RNA therapeutics at an institutional level.

No posts

Ready for more?